Anuh Pharma Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a total revenue of ₹201.29 crore for the quarter, an increase from ₹160.45 crore in the same period last year. Profit after tax for the quarter stood at ₹13.45 crore, compared to ₹10.34 crore in the corresponding quarter of the previous year. For the nine months ended December 31, 2025, total revenue was ₹578.02 crore, up from ₹471.43 crore in the previous year. The profit after tax for the nine-month period was ₹29.36 crore, a decrease from ₹34.89 crore in the prior year. EBITDA for the quarter was ₹20.91 crore (₹15.73 crore in Q3FY25), with an EBITDA margin of 10.60% (9.86% in Q3FY25). Adjusted EBITDA was ₹24.03 crore (₹16.18 crore in Q3FY25), with an adjusted EBITDA margin of 12.18% (10.14% in Q3FY25). The Board of Directors also authorized Key Managerial Personnel to determine the materiality of events or information and make necessary disclosures to the stock exchanges. The board meeting commenced at 12:30 p.m. and concluded at 5:40 p.m. on February 6, 2026.
